- Home
- RMCF vs MBRX Comparison
RMCF vs MBRX Comparison
Compare RMCF & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | MBRX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 13.1M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RMCF | MBRX |
|---|---|---|
| Price | $1.50 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 37.0K | ★ 216.0K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $0.25 |
| 52 Week High | $2.99 | $7.98 |
Technical Indicators
Market Signals| Indicator | RMCF | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 65.28 |
| Support Level | $1.50 | $2.20 |
| Resistance Level | $1.82 | $2.95 |
| Average True Range (ATR) | 0.13 | 0.20 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 13.46 | 87.10 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.